Summary
This preclinical review investigates how light exposure, mediated through melanopsin-containing intrinsically photosensitive retinal ganglion cells (ipRGCs), may enhance the efficacy of antidepressant medications. The findings suggest lighting interventions could be used as an adjunct to pharmacological treatment for depression, with implications for therapeutic lighting design in clinical settings.
Key Findings
- ipRGCs (melanopsin-expressing retinal ganglion cells) are identified as playing an important role in mood regulation, providing a biological mechanism for light-based antidepressant potentiation.
- Preclinical evidence supports the use of light as an adjunct to antidepressant medication, suggesting combined light-pharmacological approaches may be more effective than medication alone.
Categories
Mood & Mental Wellness: Examines preclinical evidence for light potentiating antidepressant medication effects via mood regulation pathways.
The Science of Light: Discusses the role of melanopsin-expressing ipRGCs in mood regulation and their interaction with psychiatric treatment.
Author(s)
S Delcourte, R Rovera, HM Cooper
Publication Year
2019
Related Publications
Mood & Mental Wellness
- The two‐process model of sleep regulation: a reappraisal
- Protecting the melatonin rhythm through circadian healthy light exposure
- Effects of artificial dawn and morning blue light on daytime cognitive performance, well-being, cortisol and melatonin levels
- Light therapy and Alzheimer's disease and related dementia: past, present, and future
- The role of daylight for humans: gaps in current knowledge
The Science of Light
- Phototransduction by retinal ganglion cells that set the circadian clock
- Color appearance models
- The mammalian circadian timing system: organization and coordination of central and peripheral clocks
- Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice
- Melanopsin is required for non-image-forming photic responses in blind mice